Category: Money tips Release Date: 2007-03-30
Source: Guangzhou Bandung
Medicine in the Northeast, led by two consecutive daily limit, pharmaceutical stocks Thursday full emergence as a hot new market, as pharmaceutical stocks, as against the concept of macro-control spending has become the second quarter of the Fund's new Masukura's core assets, so their emergence is also is very natural. This treasure, as a sub-G has a higher brand value the concept of Chinese medicine, can the shell resource, oversold low the bottom of the small-cap stocks, a new hot spot in the pharmaceutical case of doubt may start at any time.
With the advent of the era full circulation, acquisition and anti-takeover will be the market's hottest hot spot in the history of Chinese and foreign stock markets, acquisition and anti-takeover is also a market is the most exciting and most popular subjects. The G sub-Po (600,351) Due to the shareholding ratio of the first and second low and the equity ratio between the two is extremely close to the company's largest shareholder with number of 26.7248 million, while the second-largest shareholder with the number of to 2437.5 million shares, the difference between the number of holdings are less than 250 million shares, which means that if the second-largest minority shareholder of Shanxi Power Fenglingdu Zone Investment and Development Co., Ltd. with capital of around 1,100 yuan to acquire its outstanding shares, they can stable the largest shareholder sitting position, showing that it is extremely rare in the cities of Shenzhen and Shanghai, the most M & A value of "shell" resources, but also because of the company's largest shareholder when the share reform is to take Sugu approach will help increase its share of the profit income, in addition, the company is one with the main self-innovation capability and patented products of proprietary Chinese medicine concept stocks, while stocks in this category, such as Yunnan Baiyao and East A donkey-hide gelatin as the most likely out of the big cattle, so the unit is worth the long-term potential of concern.
Information shows that the company is China one of 50 proprietary Chinese medicines, but also the largest production base of transdermal preparations, has a number of core technologies with independent intellectual property rights and products, which is particularly dramatic, the company's leading products, "baby one Spirit" is a domestic production of patented exclusive brand, annual sales of 55 million, annual output value of more than 100 million yuan, up 76.43 percent of its gross margin, but also fully demonstrates the company's very strong profitability and the huge profits through monopoly. In recent years, sales of the product has maintained a stable increase of 9%, which also makes the company's operating performance has maintained sustained and rapid growth momentum. Since the company's main profit products Pediatric indigestion medicine Dinggui children is a patent umbilical paste products, to expire in 2013, showing that the unit with the concept of independent innovation of Chinese medicine and the concept of national brands, and in the secondary market on the Shanghai and Shenzhen, with independent innovation capability and national brands, such as traditional Chinese medicine concept stock Yunnanbaiyao and East A donkey-hide gelatin and so has the market to recover by the bar and become a major Niugu. In addition, the company has also set up co-operation, Beijing Medical University, Research Center of Chinese medicine, and with the China Medical University, Beijing Traditional Chinese Medicine Research Institute of Church secondary schools in close co-operation efforts in new product research and development, and establish a good relationship, forming a combination of production and research framework. The company already has 38 national patent product, very strong development potential.
G Ya Bao (600,351) as a value has been seriously underestimated, shell resource is extremely valuable, circulation is only 60 million small-cap stocks, with independent innovation capability and brand of proprietary Chinese medicine concept stock is definitely worth focusing on.
Historical Information: G Ya-Po (600,351): independent research and development to create the explosive industry to be quite a lot May 20, 2006
Source: Xiangcai Securities
Cities Xianyihouyang indicator unit pulled up and the popularity of the concentration gradually absorbed the subscription of new shares to bring short-term bearish stock stabilized in 10-day moving average at pick-up pattern of the benign operation of the establishment earlier this week, the market outlook will remain the� The disk is still a strong variety of themes to Han Quangu hot spots mainly in the plate in, pharmaceutical species there have been dark horse emerged, the Department of Medical Science and Technology, Jilin Pharmaceutical Sinopharm continuous limit-pose a great impact on the plate, with the medical industry inflection point occurs, the market will be more eyes to bar pharmaceutical industry, and as one of the 50 G-sub-Po (600,351), poised at the bottom of adequate, focus on:
My company is one of 50 proprietary Chinese medicines, has the largest production base of transdermal preparations, and has a number of core technologies with independent intellectual property rights and products, product quality is steady and the market share continues to increase. In recent years, sales of the product has maintained a stable increase of 9% for the company's operating performance to maintain good growth momentum and lay a foundation. In 2005, the implementation of self-development and joint development of integrated, high-tech product development and market prospects of the combined product imitation, and focus on the declaration of patented products, the new open issue 64, successfully completed the Fenglingdu Industrial Park, sub-Po Pharmaceutical Taiyuan Pharmaceutical Co., Ltd. and four Chuanya Baoguang Thailand Co., Ltd. investment and construction, and all passed the GMP certification, as these companies gradually on the right track, but also the company is expected to bring new growth points.
Co-operation with Medical University, Beijing set up a traditional Chinese medicine research center, and with the China Medical University, Beijing Traditional Chinese Medicine Research Institute of Church secondary schools in close co-operation efforts in new product research and development, production scale in recent years, the company expanded. Company active in investment and construction of new projects and production line technological transformation, now has 38 national patents. Company plans to invest an annual average of new product research and development costs 40 million yuan, the cumulative cost of more than 200 million yuan invested to strengthen the Beijing Traditional Chinese Medicine Research Center and Technical Center, Taiyuan Asian merchants, R & D capabilities, consolidate the basis of independent innovation enterprises, and strengthen intellectual property rights protection, focusing on patents, trademarks declaration towards the end of 2007, reporting more than 40 invention patents, utility patents than 100. These pairs of stronger enterprises, expanding the competitive advantage, cultivating core competitiveness of enterprises will play an active role.
The company's industry monopoly, and high-growth power sector has been recognized, open-end funds, pension funds continue to overweight, the trend along the trend line on a steady climbed, the main force in order to accumulation in the current price still mainly a bargaining chip once the collection is completed, the explosive will not be discounted, investors can focus on.
